ClinicalTrials.gg
CompletedNCT03487783Updated Dec 29, 2020

Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette's Syndrome

A Phase 3 interventional study of Aripiprazole Oral Solution and Placebo Oral Solution in Tourette Syndrome, sponsored by Otsuka Beijing Research Institute. Completed at 1 site in China. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-12-29.

Sponsored by Otsuka Beijing Research Institute (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing aripiprazole in Tourette Syndrome — none open to participants now, none under way, none of them phase 3. Aripiprazole · Tourette Syndrome.

Enrollment
4th of 10
121 · median 97
Started
2018
with 1 other
Phase 3
7 of 10
none open now
Registered
9th of 10
by date
Lead sponsor
1 of 10
Otsuka Beijing Research Institute

Among the 10 studies testing aripiprazole in Tourette Syndrome, this one is the 4th largest by enrollment, is one of 2 that started in 2018, is one of 7 in phase 3, and was the 9th registered.

Tourette Syndrome

240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.

Browse Tourette Syndrome studies →

Open to participants now

None of the 10 studies testing aripiprazole in Tourette Syndrome is open now. The open studies under Tourette Syndrome, anywhere →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing aripiprazole in Tourette Syndrome as a file.
02

Study summary

This study is a multicenter, randomized, double-blind, placebo-controlled trial designed to assess the safety, efficacy, tolerability and steady-state plasma trough concentration of flexible-dosed aripiprazole once-daily administration in children and adolescents with Tourette's syndrome. A total of around 120 subjects will be randomized to aripiprazole (2\~20 mg) or placebo in a 1:1 ratio (approximately 60 subjects in each group), for treatment of 8 weeks.

Read the detailed description

Screening phase: It can last up to 42 days, including the screening visit (V1), a washout period when applicable, additional screening visit (V1a) and baseline visit (V2). The screening phase will serve the following purposes: 1) To allow for appropriate washout of prohibited medications; 2) To review the screening data; 3) To establish a pretreatment baseline of critical outcome measures.

Treatment phase: It lasts 8 weeks; the purpose of the treatment phase is to assess the efficacy, safety, tolerability and steady-state plasma trough concentration of aripiprazole in the treatment of children and adolescents with Tourette's syndrome.

Safety follow-up phase: All subjects will be followed up for safety (adverse events) at Day 16 after the final medication via telephone

03

Conditions studied

  • Tourette Syndrome

Browse trials for

Keywords

  • Tourette
  • Aripiprazole Oral Solution
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written form must be obtained from a legal guardian (and the subject)
  2. The subject and the designated guardian(s) or caregiver(s) are able to comprehend and satisfactorily comply with the protocol requirements, as evaluated by the investigator.
  3. The subject is a male or female child or adolescent, 6-18 years of age (6≤ Age \<18) at the time of Baseline Visit (V2);
  4. The subject meets the current diagnostic criteria for Tourette's syndrome and requires drug therapy;
  5. The subject has a TTS ≥ 22 on the YGTSS at Baseline Visit (V2);

Exclusion criteria

Exclusion Criteria:

  1. Women of (WOCBP) who will not commit to utilizing the approved methods or who will not remain abstinent during the trial and for 8 weeks following the final dose of study drug; Note: WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not [defined as amenorrhea 12 consecutive months; or women on hormone replacement therapy with documented serum follicle stimulating hormone level ≥ 35 mIU/mL].
  2. Females who have a positive pregnancy test result or who are pregnant or breast-feeding;
  3. Subjects who have secondary tic symptoms accompanied by late-onset tics, Huntington's chorea, neuroacanthocytosis, mental retardation, or autism;
  4. Subjects who have comorbidities requiring drug therapy, such as attention deficit / attention-deficit hyperactivity, obsessive-compulsive disorder, or oppositional defiant disorder (if a case is judged by the investigator that drug therapy is not required for any of the above diseases during this study, then the patient is eligible to participate in this trial);
  5. Subjects who have lower intelligence;
  6. Subjects who have a current diagnosis of bipolar disorder, mental disorder, schizophrenia, or depressive disorder;
  7. Subjects who have records of neuroleptic malignant syndrome;
  8. Subjects who have experienced episodes of epileptic seizure in the past year;
  9. Subjects who have a history of severe traumatic brain injury or stroke;
  10. Subjects who have any unstable medical conditions or are currently ill (e.g., congenital heart disease, arrhythmia or cancer), which, in the investigator's judgment, will put them at a risk of major adverse event during this trial, or will interfere with safety and efficacy assessments
  11. Subjects who require both drug therapy and cognitive-behavioral therapy (CBT, including habitual inversion therapy, cognitive therapy, relaxation training, etc.) during the trial period;
  12. Patients with the following laboratory test results, vital signs, measurements, and (ECG) results will be excluded:

    • > 450 msec (male), QTc > 470 msec (female)
    • (\< lower limit)
    • (\< lower limit)
    • Neutrophils (\< lower limit)
    • (SGOT) or ALT (SGPT) (> upper limit)
    • Creatinine (> upper limit) Subjects should be excluded if they have any other abnormal laboratory tests, vital sign results, or ECG findings which in the investigator's judgment is medically significant and will impact the safety of the subject or the interpretation of the trial results;
  13. Subjects who have a body weight of lower than 15 kg;
  14. Subjects who have been known to be with allergy or to aripiprazole or other dihydroquinolones (e.g., carteolol, vesnarinone and cilostazol);
  15. Subjects who have participated in any clinical trial of any drugs within the past one month;
  16. Subjects who may require concomitant treatments prohibited as per the protocol during the trial period (referring to Section 7 Prohibited and Restricted Therapies);
  17. Subjects who were previously enrolled in clinical trials of aripiprazole (excluding investigator-sponsored trials);
  18. Subjects who are considered to have developed resistance to antipsychotic drugs by the investigator due to lack of efficacy after receiving 2 different antipsychotic drugs at reasonable doses and at least 3 weeks of treatment with each respectively;
  19. Subjects who are considered to have developed resistance to aripiprazole by the investigator due to lack of efficacy after an adequate time of treatment with adequate dose;
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
121 participants (actual)

Study arms

  • Experimental
    Aripiprazole Oral Solution

    1 mg/mL, 2-20 mg/day (2-20 mL/day), once daily for 8 weeks, administered at about the same time every day, either before or after meal

    Drug: Aripiprazole Oral Solution

  • Placebo comparator
    Placebo Oral Solution

    2-20 mg/day (2-20 mL/day), once daily for 8 weeks, administered at about the same time every day, either before or after meal

    Drug: Placebo Oral Solution

Interventions

  • Aripiprazole 2-20 mg/day (2-20 mL/day)

    Also known as: Aripiprazole OS, Abilify

  • DrugPlacebo Oral Solution

    Placebo 2-20 mg/day (2-20 mL/day)

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Changes from Baseline to Week 8 (or endpoint) in YGTSS TTS.

    The objective of the primary analysis is to compare the efficacy of flexible-dosed aripiprazole oral solution (2\~20 mg/day) with placebo in the suppression of tics in children and adolescents with a diagnosis of Tourette's syndrome. The efficacy is assessed by the changes of total tic scores (TTS) from randomization to the last visit (Week 8) on the Yale Global Tic Severity Scale (YGTSS).

    Time frame: Baseline and 8 weeks (or endpoint)

Secondary outcomes

  1. Percentage change from Baseline to Week 8 (or endpoint) in YGTSS TTS;

    The efficacy is assessed by the percentage subjects changes of total tic scores (TTS) from randomization to the last visit (Week 8) on the Yale Global Tic Severity Scale (YGTSS)

    Time frame: Baseline and 8 weeks (or endpoint)

  2. Response rate on TS-CGI Improvement scale

    The response rate (the percentage of patients with a score of 1 or 2) is assessed by TS-CGI Improvement scale from Baseline to Week 8 (or endpoint)

    Time frame: Baseline and 8 weeks (or endpoint)

  3. Partial remission rate on TS-CGI Improvement scale

    The partial remission rate (the percentage of patients with a score of 3) is assessed by TS-CGI Improvement scale from Baseline to Week 8 (or endpoint)

    Time frame: Baseline and 8 weeks (or endpoint)

  4. Changes from Baseline to Week 8 (or endpoint) in TS-CGI Severity scale scores

    The efficacy is assessed by changes from Baseline to Week 8 (or endpoint) in TS-CGI Severity scale scores

    Time frame: Baseline and 8 weeks (or endpoint)

07

Study locations

1 site
  • Beijing Anding Hospital of Capital Medical University
    Beijing, Beijing 100088, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2018 to primary completion in Feb 2020, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2018
First posted
Apr 4, 2018
StartActual
May 2, 2018
Primary completionActual
Feb 14, 2020
CompletionActual
Feb 14, 2020
Last update
Dec 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03487783
Responsible party
Sponsor
First posted
Apr 4, 2018
Start date
May 2, 2018
Primary completion
Feb 14, 2020
Completion
Feb 14, 2020
Last update
Dec 29, 2020

Study contacts

Patyman Juma
study director · Otsuka Beijing Research Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion